M. Bannink

654 total citations
22 papers, 448 citations indexed

About

M. Bannink is a scholar working on Oncology, Biological Psychiatry and Public Health, Environmental and Occupational Health. According to data from OpenAlex, M. Bannink has authored 22 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Biological Psychiatry and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in M. Bannink's work include Tryptophan and brain disorders (7 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Bipolar Disorder and Treatment (3 papers). M. Bannink is often cited by papers focused on Tryptophan and brain disorders (7 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Bipolar Disorder and Treatment (3 papers). M. Bannink collaborates with scholars based in Netherlands, Belgium and Gabon. M. Bannink's co-authors include Arthur R. Van Gool, Wim H.J. Kruit, G. Stoter, Stefan Sleijfer, Durk Fekkes, Alexander Eggermont, Ron H.J. Mathijssen, Teun van Gelder, Lisette Binkhorst and Agnes Jager and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Clinical Pharmacokinetics.

In The Last Decade

M. Bannink

22 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Bannink Netherlands 11 125 85 70 69 63 22 448
Antonio Diez‐Ruiz Austria 10 51 0.4× 116 1.4× 80 1.1× 88 1.3× 166 2.6× 18 536
Özlem Demirpençe Türkiye 11 104 0.8× 38 0.4× 89 1.3× 59 0.9× 47 0.7× 32 397
Katarzyna A. Lisowska Poland 15 80 0.6× 198 2.3× 94 1.3× 83 1.2× 57 0.9× 46 626
Morteza Bagheri Iran 13 38 0.3× 112 1.3× 44 0.6× 133 1.9× 47 0.7× 64 629
Dietmar Fuchs Austria 12 36 0.3× 90 1.1× 64 0.9× 112 1.6× 85 1.3× 18 491
Rachel Howard United States 11 191 1.5× 59 0.7× 24 0.3× 76 1.1× 59 0.9× 20 555
Juan Ouyang China 13 37 0.3× 125 1.5× 146 2.1× 131 1.9× 23 0.4× 35 577
Xuesong Gao China 14 45 0.4× 58 0.7× 24 0.3× 263 3.8× 69 1.1× 47 493
Diana Pang United States 8 223 1.8× 94 1.1× 25 0.4× 293 4.2× 47 0.7× 9 716
Giusy Messina Italy 9 80 0.6× 52 0.6× 39 0.6× 105 1.5× 22 0.3× 36 368

Countries citing papers authored by M. Bannink

Since Specialization
Citations

This map shows the geographic impact of M. Bannink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Bannink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Bannink more than expected).

Fields of papers citing papers by M. Bannink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Bannink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Bannink. The network helps show where M. Bannink may publish in the future.

Co-authorship network of co-authors of M. Bannink

This figure shows the co-authorship network connecting the top 25 collaborators of M. Bannink. A scholar is included among the top collaborators of M. Bannink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Bannink. M. Bannink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Binkhorst, Lisette, M. Bannink, Peter de Bruijn, et al.. (2015). Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clinical Pharmacokinetics. 55(2). 249–255. 21 indexed citations
2.
Binkhorst, Lisette, M. Bannink, Peter de Bruijn, et al.. (2014). First Intra-Patient Comparison of Antidepressant Use Among Tamoxifen Patients. Annals of Oncology. 25. iv106–iv106. 2 indexed citations
3.
Binkhorst, Lisette, Ron H.J. Mathijssen, Myrthe P. P. van Herk‐Sukel, et al.. (2013). Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Research and Treatment. 139(3). 923–929. 49 indexed citations
4.
Oldenmenger, Wendy H., et al.. (2011). Higher doses of opioids in patients who need palliative sedation prior to death: Cause or consequence?. European Journal of Cancer. 47(15). 2341–2346. 15 indexed citations
5.
Dooren, S. van, H.J. Duivenvoorden, Jan Passchier, et al.. (2009). The Distress Thermometer assessed in women at risk of developing hereditary breast cancer. Psycho-Oncology. 18(10). 1080–1087. 13 indexed citations
6.
Gool, Arthur R. Van, Robert Verkerk, Durk Fekkes, et al.. (2008). Plasma Activity of Prolyl Endopeptidase in Relation to Psychopathology During Immunotherapy with IFN- α in Patients with Renal Cell Carcinoma. Journal of Interferon & Cytokine Research. 28(5). 283–286. 4 indexed citations
7.
Fekkes, Durk, Arthur R. Van Gool, M. Bannink, et al.. (2008). Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy. Amino Acids. 37(4). 703–708. 3 indexed citations
8.
Gool, Arthur R. Van, Robert Verkerk, Durk Fekkes, et al.. (2008). Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status. Psychiatry and Clinical Neurosciences. 62(5). 597–602. 21 indexed citations
9.
Bannink, M., Wim H.J. Kruit, Arthur R. Van Gool, et al.. (2008). Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated. Psychosomatics. 49(1). 56–63. 8 indexed citations
10.
Boer, Angela G. E. M. de, et al.. (2008). Werkhervatting bij kanker: wetenschappelijk onderbouwd. Tijdschrift voor bedrijfs- en verzekeringsgeneeskunde. 16(7). 285–291. 3 indexed citations
11.
Bannink, M., Durk Fekkes, Arthur R. Van Gool, et al.. (2007). Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects. Neuropsychobiology. 55(3-4). 225–231. 15 indexed citations
12.
Echteld, Michael A., Lia van Zuylen, M. Bannink, Erica Witkamp, & Carin C.D. van der Rijt. (2007). Changes in and correlates of individual quality of life in advanced cancer patients admitted to an academic unit for palliative care. Palliative Medicine. 21(3). 199–205. 17 indexed citations
13.
Fekkes, Durk, M. Bannink, Wim H.J. Kruit, et al.. (2006). Influence of pegylated interferon-α therapy on plasma levels of citrulline and arginine in melanoma patients. Amino Acids. 32(1). 121–126. 13 indexed citations
14.
Sleijfer, Stefan, M. Bannink, Arthur R. Van Gool, Wim H.J. Kruit, & G. Stoter. (2005). Side Effects of Interferon-α Therapy. Pharmacy World & Science. 27(6). 423–431. 193 indexed citations
15.
Gool, Arthur R. Van, Heidi H. van Ojik, Wim H.J. Kruit, et al.. (2004). Serum Activity of Prolyl Endopeptidase, but Not of Dipeptidyl Peptidase IV, Is Decreased by Immunotherapy with IFN- α in High-Risk Melanoma Patients. Journal of Interferon & Cytokine Research. 24(7). 411–415. 8 indexed citations
16.
Bannink, M., Wim H.J. Kruit, Arthur R. Van Gool, et al.. (2004). Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29(1). 109–114. 4 indexed citations
17.
Gool, Arthur R. Van, Heidi H. van Ojik, Wim H.J. Kruit, et al.. (2004). Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. Anti-Cancer Drugs. 15(6). 587–591. 13 indexed citations
18.
Gool, Arthur R. Van, Durk Fekkes, Wim H.J. Kruit, et al.. (2003). Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Research. 119(1-2). 125–132. 31 indexed citations
19.
Berk, L, Arthur R. Van Gool, M. Bannink, & Wim H.J. Kruit. (1999). [Side effects of interferon alfa].. PubMed. 143(28). 1461–4. 3 indexed citations
20.
Gool, Arthur R. Van, Wim H.J. Kruit, J.J. Cornelissen, et al.. (1999). Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatrica. 11(4). 120–124. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Diez‐Ruiz Breakdown of academic impact, for papers by Özlem Demirpençe Breakdown of academic impact, for papers by Katarzyna A. Lisowska Breakdown of academic impact, for papers by Morteza Bagheri Breakdown of academic impact, for papers by Dietmar Fuchs Breakdown of academic impact, for papers by Rachel Howard Breakdown of academic impact, for papers by Juan Ouyang Breakdown of academic impact, for papers by Xuesong Gao Breakdown of academic impact, for papers by Diana Pang Breakdown of academic impact, for papers by Giusy Messina
Rankless by CCL
2026